Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-5366 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes

Next Previous
Trial Profile

A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-5366 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABI 5366 (Primary)
  • Indications Herpes genitalis; Herpes simplex virus type 2 infections
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Assembly Biosciences

Most Recent Events

  • 09 Apr 2026 According to an Assembly Biosciences media release, Phase 1b interim results data from ABI-1179 accepted for late-breaker poster presentation on April 21, 2026, at 12:00 PM CEST at at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) taking place April 17-21, 2026, in Munich, Germany.
  • 30 Mar 2026 Status changed from active, no longer recruiting to completed.
  • 21 Nov 2025 Planned End Date changed from 1 Dec 2025 to 1 Feb 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top